Neuropsychology plays a critical role in understanding cognitive decline in neurodegenerative diseases. This page covers neuropsychological assessment approaches, testing methodologies, and their applications in diagnosing and tracking disease progression in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, frontotemporal dementia (FTD), and Huntington's disease (HD)[1].
| Test | Description | Applications |
|---|---|---|
| MMSE (Mini-Mental State Examination) | 30-point screening tool | AD screening, baseline cognitive assessment[2] |
| MoCA (Montreal Cognitive Assessment) | 30-point alternative to MMSE | Detects mild cognitive impairment[3] |
| MMSE 2 | Updated version with improved sensitivity | Standardized cognitive screening |
Cognitive test performance is influenced by:
Higher cognitive reserve (education, occupational complexity) allows greater pathology before clinical symptoms appear[7].
Neuropsychological findings correlate with:
| Imaging Finding | Cognitive Correlation |
|---|---|
| Hippocampal atrophy | Episodic memory decline |
| Frontal lobe changes | Executive dysfunction |
| Temporal lobe involvement | Language impairment |
| White matter lesions | Processing speed |
Mild Cognitive Impairment (MCI) represents a critical intermediate state between normal aging and dementia[14]. Understanding the neuropsychological profiles in MCI is essential for early detection and intervention.
| Type | Cognitive Profile | Progression Risk |
|---|---|---|
| Amnestic single domain | Memory impairment only | Highest progression to AD |
| Amnestic multiple domain | Memory + other domains | High progression to AD |
| Non-amnestic single domain | Non-memory impairment | Often progresses to other dementias |
| Non-amnestic multiple domain | Multiple non-memory deficits | Variable progression |
According to Jak et al. (2009), MCI can be classified based on neuropsychological profiles[15]:
| Profile | 5-Year Conversion Rate |
|---|---|
| Amnestic single domain | 40-50% to AD |
| Amnestic multi-domain | 50-60% to AD |
| Non-amnestic | Variable, often to non-AD dementia |
Combining neuropsychological testing with neuroimaging enhances diagnostic accuracy:
| Biomarker | Neuropsychological Correlation |
|---|---|
| Amyloid PET (positive) | Memory domain deficits |
| FDG-PET (temporal hypometabolism) | Episodic memory impairment |
| Hippocampal volume | Delayed recall performance |
| White matter hyperintensities | Processing speed, executive |
| Marker | Cognitive Correlation |
|---|---|
| Low Aβ42 | Memory impairment in prodromal AD |
| High tau/p-tau | Executive dysfunction |
| Neurofilament light (NfL) | Global cognitive decline |
Neuropsychological testing is used to:
Accounting for test-retest variability is essential:
| Test | Typical Change | Reliable Change (95% CI) |
|---|---|---|
| MMSE | ±1 point | ±3 points |
| RAVLT delay | ±2 words | ±4 words |
| Trail Making B | ±20 sec | ±45 sec |
Combining multiple tests improves sensitivity:
| Composite | Component Tests | Clinical Use |
|---|---|---|
| ADAS-Cog | Memory, language, praxis | AD clinical trials |
| MCI screen | Memory, attention | MCI detection |
| Executive composite | Trail Making, Stroop, WCST | Frontotemporal assessment |
Salmon DP, Bondi MW. Neuropsychological assessment of dementia. Annu Rev Psychol. 2009. ↩︎
Folstein MF, Folstein SE. Mini-mental state examination. Psychiatry Res. 1988. ↩︎
Nasreddine ZS, et al. The Montreal Cognitive Assessment (MoCA). J Am Geriatr Soc. 2005. ↩︎
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984. ↩︎
Sahakian BJ, et al. Computerized learning test. Psychopharmacology. 1985. ↩︎
Salthouse TA. Individual differences in cognitive aging. J Clin Exp Neuropsychol. 1991. ↩︎
Stern Y. Cognitive reserve in aging and Alzheimer's disease. Lancet Neurol. 2012. ↩︎
Clark CM, et al. Variability in annual Mini-Mental State Examination. Neurology. 1999. ↩︎
Petersen RC, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001. ↩︎
Williams-Gray CH, et al. Cognitive deficits and psychosis. Brain. 2006. ↩︎
Rascovsky K, et al. Diagnostic criteria for behavioral variant FTD. Brain. 2011. ↩︎
Paulsen JS, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001. ↩︎
Phukan J, et al. The syndrome of frontotemporal dementia in ALS. Lancet Neurol. 2011. ↩︎
Winblad B, et al. Mild cognitive impairment beyond controversies. Lancet Neurol. 2004. ↩︎
Jak AJ, et al. Classification of neuropsychological profiles in MCI. Neurology. 2009. ↩︎